A pill to stop the bleeding? new hope for HHT nosebleeds
NCT ID NCT07743671
First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether an experimental oral drug called engasertib can reduce the number of nosebleeds in adults with moderate to severe hereditary hemorrhagic telangiectasia (HHT), a genetic condition that causes abnormal blood vessels and frequent bleeding. About 240 participants will receive either engasertib or a placebo daily for 28 weeks. The main goal is to see if the drug lowers the total number of nosebleed episodes compared to placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- engasertib (also called VAD044), taken as an oral capsule
- What this could lead to
- If it works, engasertib could become the first approved treatment to reduce frequent nosebleeds in people with HHT, improving daily life and reducing the need for transfusions.
- What could go wrong
- This is a phase 3 trial, but success is not guaranteed. The drug may not reduce nosebleeds more than a placebo, and side effects are possible. Results will need to be confirmed in this larger study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY HEMORRHAGIC TELANGIECTASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Massive HHT registry aims to unlock secrets of rare bleeding disorder
- Blood thinners in HHT: a risky balancing act under the microscope
- Can a transplant drug stop HHT nosebleeds? small study tests sirolimus
- New antibody aims to tame rare bleeding disorder
- New drug aims to stop nosebleeds in rare blood vessel disorder
- Could a common heart drug tame nosebleeds in rare disease?